Introduction
Capsaicin, a pungent ingredient of chili peppers, excites nociceptive neurons by stimulating capsaicin receptors on the nerve endings. 1, 2 Capsaicin receptor was cloned and named as vanilloid receptor 1 or transient receptor potential ganglionic neurons has been demonstrated, and the channels are now believed to be a molecular integrator of inflammatory pain sensation. The essential roles of TRPV1 for pain sensation have been strongly supported by mice lacking TRPV1 that were impaired in the detection of painful inflammatory stimuli, painful vanilloids, and heat. 5 Because TRPV1 is a good target of analgesics for inflammatory pain, many pharmaceutical companies have tried to identify novel and potent TRPV1 modulators. TRPV1 targeting analgesics are classified into two groups: TRPV1 antagonists and TRPV1 agonists. Although small molecular synthetic TRPV1 antagonists with improved toxicity are the major focus of development, local treatment of TRPV1 agonists has been tried in clinical practice. The strong TRPV1 activators capsaicin and resiniferatoxin initially excite TRPV1 and then produce a strong desensitization of the channels or irreversibly destroy capsaicin-sensitive sensory neurons. For this reason, capsaicin-based TRPV1 agonists can be used when they are topically applied by injection or patches. Successful TRPV1-agonist-based therapy has been reported for osteoarthritis, postherpetic neuropathy, painful HIV-associated sensory neuropathy, cluster headache, migraine, urinary incontinence, and overactive bladder. 6 Disadvantages of TRPV1 agonists include a burning sensation and the need for multiple applications to get sufficient therapeutic effects. Therefore, identifying and developing new TRPV1 agonists with reduced pungency compared with capsaicin-based agonists and a higher chemical stability have been a matter of great interest.
2-Aminoethoxydiphenyl borate (2-APB) has been described as an inhibitor of inositol 1,4,5-trisphosphate receptor (IP 3 -R)-induced Ca 2+ release from intracellular stores. 7 Later studies, however, have revealed that 2-APB is not IP 3 -R specific, but has many targets. For example, 2-APB inhibits a native store-operated calcium entry (SOCE) channels [8] [9] [10] and many transient receptor potential cation (TRPC) and transient receptor potential melastatin channels, 11, 12 endoplasmic reticulum Ca 2+ -ATPases 13 and volume-regulated anion channels, 14 but it activates phospholipase C. 15 This complexity renders 2-APB as a poor tool for the separation of IP 3 -R and SOCEs from other Ca 2+ entry pathways.
2-APB was found to be a common activator of three thermosensitive TRPV channels: TRPV1, TRPV2, and TRPV3. 16, 17 With a whole-cell patch clamp recording, it was shown that 2-APB strongly activated mouse TRPV1 and stimulated the response to capsaicin, heat, and acid. 16, 17 In addition, 2-APB sensitized native nociceptive neurons to heat in a mouse model. 18 For this reason, it is suggested that 2-APB analogues could be attractive candidates for the development of a selective TRPV1 agonist or antagonist. However, it has been noticed that 2-APB has no effect on TRPV2 and shows a very weak effect on activating TRPV1 expressed in human embryonic kidney (HEK) cells. 19 This discrepancy remains to be explained.
Therefore, we aimed to establish whether the heterogeneously expressed TRPV1 channels are directly activated by 2-APB and to prove the potentiation of 2-APB on the effects of capsaicin, heat, and protons on the channels. To this purpose, we recorded rat TRPV1 (rTRPV1) channels using excised membrane patches, because the previously reported were mainly achieved by whole-cell patch clamp recordings and mouse TRPV1. 16, 19 Recording of TRPV1 current by whole-cell patch clamp cannot exclude the cytoplasmic components and signaling molecules that influence overall activity of the channels. Many cytoplasmic molecules including protein kinase C and calmodulin kinase modulate TRPV1 activity. 20, 21 Assuming that these signaling molecules are relatively well conserved in whole-cell patch recordings, the demonstration of TRPV1 activation by 2-APB from a cell-free patches can rule out their contribution and can distinguish from an indirect activation mechanism.
Methods

Cell culture and expression of rTRPV1
HEK 293 cells were cultured at 37 • C, 5% CO 2 , in Dulbecco's minimal essential medium (DMEM, Gibco, Grand Island, NY, USA) containing 4.5 mg/mL glucose, 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, 100 g/mL streptomycin. Rat TRPV1 cDNA was kindly provided Dr Uhtaek Oh (Seoul National University, Korea 
Patch clamp
HEK cells that fluoresced green underlight of wavelength 588 nm were considered to be transfected with rTRPV1 and were selected for recording. Patch clamp recordings were performed at room temperature (23) (24) (25) (26) • C) with the inside-out and outside-out configurations. Conventional whole-cell recordings were performed to verify the responses in outside-out configuration. Signals were amplified with an Axopatch 1D patch clamp amplifier and controlled with pClamp software 7.0 (Axon Instruments). Signals were filtered at 1 kHz and recorded at 5 kHz. For the inside-out patch clamp, pipettes were pulled from micropipette glass (World Precision Instruments Inc, Sarasota, FL, USA) to 1.5-2 M tip resistance and filled with an extracellular (pipette) solution containing 140 mM NaCl and 10 mM Hepes (pH 7.3 with N-methyl-Dglucamin). The cytoplasmic (bath) solution contained 140 mM NaCl, 10 mM Hepes, and 2 mM EGTA (pH 7.2 with N-methyl-D-glucamin). The current was recorded at a holding potential of -60 mV. For outside-out patch clamp, the same cytoplasmic (pipette) and extracellular (bath) solutions, as used in the inside-out patches, were used. Whole-cell currents were recorded in a nominal Ca 2+ free extracellular (bath) solution contained 145 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , and 10 mM glucose(pH 7.4). Outside-out and whole-cell currents were recorded at a holding potential of -30 mV. 
Chemicals and reagents
All chemicals used were purchased from Sigma-Aldrich (St Louis, MO, USA). Stock solutions of 2-APB, diphenylborinic anhydride (DPBA), capsaicin, and capsazepine were prepared in dimethyl sulfoxide. Drugs were diluted in the appropriate solutions to the desired final concentrations prior to use.
Statistics
Data are presented as mean ± standard error of the mean with n of sample number. Statistical comparison was tested using unpaired t test and significance was set at p < 0.05.
Results
Activation of rTRPV1 channels by 2-APB
To prove the functional expression of rTRPV1 channels in HEK 293 cells, we first recorded the capsaicin-activated current with the inside-out patch configuration. To prevent a rapid desensitization of the current, we perfused the patch membrane with a Ca 2+ -free cytoplasmic (bath) solution containing 1 mM EGTA and 140 mM Na + . At a holding potential of -60 mV, capsaicin dose-dependently activated an inward rTRPV1 current with no significant desensitization, indicating that the expressed channels are functional and are properly detected from excised patch membranes ( Fig. 1 ). Capsaicinactivated rTRPV1 current was strongly inhibited by a TRPV1 antagonist capsazepine (10 M; Fig. 1A ). Half maximal concentration of capsaicin was 21.2 ± 5 M (n = 8; Fig. 1B ,C). In excised patches, the amplitudes of the capsaicin-activated currents were so variable that it was not possible to compare the current obtained from a different patch. Initially, we tried to measure density of the currents by normalizing the current with a measured membrane capacitance. However, the normalized data were also very variable, so we concluded that this was probably due to a different expression level of the channels. The patch membranes were easily broken at capsaicin concentrations > 50 M, so we did not use capsaicin at > 10 M. We investigated whether 2-APB activates rTRPV1 channels in excised patch membranes. In the inside-out patch mode, cytoplasmic application of 2-APB activated an inward rTRPV1 current at a holding potential of -60 mV (Fig. 2Ai) . Capsazepine (10 M) strongly inhibited the 2-APB-activated currents suggesting that 2-APB activates rTRPV1 channels. 2-APB dose-dependently activated the current and the estimated half maximal effective concentration value for 2-APB was 277.6 ± 64.5 M at a holding potential of -60 mV (n = 6, data not shown). In outside-out patches mode, inclusion of 1 mM 2-APB into the recording pipette weakly activated rTRPV1 current (Fig. 2Ai) . The same results were obtained from wholecell recordings. This was somewhat unexpected, because the same concentration of 2-APB strongly activated the current when applied from the cytoplasmic side of the inside-out patches (Fig. 2Ai) . We therefore thought that if interference by unknown factors reduces available 2-APB, it could be overcome by raising the concentration of the compound in the pipette. To test this possibility, we raised the intrapipette 2-APB up to 5 mM and the outside-out patches were achieved. As shown in Fig. 2Aiii , 5 mM 2-APB slowly activated the capsaicinsensitive current after achieving the outside-out patches. In this condition, application of 100-500 M 2-APB into the extracellular space, which is much lower than intrapipette 2-APB, slightly activated the current. This indicates that, 2-APB has binding sites not only on the cytoplasmic but also extracellular side.
To determine whether the extracellular 2-APB activates rTRPV1, we recorded the current in outside-out patch mode. As shown in Fig. 2Bi , 0.5-1 mM 2-APB applied into the extracellular side of the outside-out patch membrane activated the capsaicin-sensitive current. In Fig. 2Bii , we included 5 mM 2-APB in the inside-out pipette solution. When the inside-out patch membranes were excised from the cells, a detectable current could be recorded. In the presence of 5 mM of extracellular 2-APB, addition of 2-APB (0.1-5 mM) into the cytoplasmic solution strongly activated the current (Fig. 2Bii) . Therefore, the results confirm that 2-APB's binding sites are located on both sides of the membrane. 
3.2.
Potentiation of the capsaicin-activated rTRPV1 current by cytoplasmic 2-APB The effect of 2-APB on the capsaicin-activated rTRPV1 current (I cap ) was investigated in the inside-out patches. To this end, we applied 2-APB either from the intracellular side or extracellular side of the inside-out patch membrane, and the changes in amplitudes of I cap were compared. For this comparison, we added 1 mM 2-APB simultaneously with 10 M capsaicin at the end of each recording and the obtained maximum I cap was used to normalize a given current.
As shown in Fig. 3A , capsaicin (0.1-10 M) dosedependently activated I cap and 1 mM 2-APB added from cytoplasmic face further increased the current. Cytoplasmic application of 2-APB with increasing concentrations of 0.1 mM, 0.5 mM, and 1 mM increased I cap (Fig. 3) . As illustrated in Fig. 3E , the I cap activated by 3 M capsaicin was increased from 3.1 ± 0.7% (n = 11) to 5.5 ± 1.7% (n = 9), 9.7 ± 4.1% (n = 5, p < 0.05), and 35.8 ± 10.2% (n = 9, p < 0.01) by 0.1 mM, 0.5 mM, and 1 mM 2-APB, respectively. I cap activated by 10 M capsaicin was increased from 10.8 ± 2.7% (n = 11) to 29.5 ± 6.8% (n = 9, p < 0.05), 34.8 ± 10.4% (n = 5, p < 0.01), and 100% (n = 9, p < 0.01) by 0.1 mM, 0.5 mM, and 1 mM 2-APB, respectively.
Potentiation of the 2-APB-activated rTRPV1 current by capsaicin
To prove the reciprocal stimulation between capsaicin and 2-APB, we tested whether the pretreatment of capsaicin potentiates the 2-APB-induced opening of rTRPV1 channels. As illustrated in Fig. 4 , pretreatment of an increasing concentrations of capsaicin (0.3-1 M) strongly potentiated the current activated by intracellular 2-APB. In the absence of capsaicin, the 1 mM 2-APB-evoked current (4.79 ± 1.4%, n = 4) increased to 10.37 ± 4.4% (n = 3), 12.8 ± 5.1% (n = 3), and 43.4 ± 13.2% (n = 6, p < 0.05) by 0.3 M, 0.5 M, and 1 M capsaicin (Fig. 4E). 
3.4.
Potentiation of the capsaicin-activated rTRPV1 current by extracellular 2-APB In Fig. 5 , increasing concentrations of 2-APB (0.1-1 mM) were included in the inside-out patch pipette to stimulate the channels from the outside of the membrane. As previously indicated, < 1 mM of extracellular 2-APB weakly activated the channels and no significant current was monitored until capsaicin was added into the cytoplasmic solution. In this condition, extracellular 2-APB dose-dependently potentiated I cap as does in the cytoplasmic side. The 10 M capsaicinactivated I cap in the presence of 100 M 2-APB (10.8 ± 3.8%, n = 9) was not different from the control shown in Fig. 3 (10.8 ± 2.7%). As shown in Fig. 5B-D , 0.5 mM and 1 mM 2-APB significantly potentiated the I cap to 48.5 ± 4.9% (n = 5, p < 0.01) and 67.4 ± 11.8% (n = 4, p < 0.01), respectively.
Potentiation effect of 2-APB on I cap was further demonstrated by the whole-cell recordings (Fig. 6) . In wholecell mode, 2-APB activated the capsaicin-sensitive current (Fig. 6A) , and I cap was strongly potentiated by 2-APB in a dosedependent manner (Fig. 6B) . These data strongly indicate that 2-APB and capsaicin reciprocally potentiate the opening of rTRPV1 channels.
Potentiation of the heat-and H + -activated rTRPV1 current by 2-APB
The effect of 2-APB on the heat-activated rTRPV1 current was investigated (Fig. 7) . In the inside-out configuration, the perfusion of preheated (at 50 • C) bath solution rapidly activated rTRPV1 currents. Usually, the heat-gated current rapidly desensitizes and the channels hardly respond to the next challenge. For this reason, we compared the response to 2-APB from different patches. When heat-activated rTRPV1 current started to desensitize, we challenged 1 mM 2-APB-containing heated solution. As shown in Fig. 7B , 2-APB added in the middle of desensitization strongly activated the current and reduced the speed of desensitization. In the next step, we examined whether 2-APB-activated currents are potentiated by extracellular protons. To this end, we applied weak acid to the inside-out pipette solution by preparing the solution at pH 6.3, and the effect of acid on the 2-APB-activated current was compared to the control at pH 7.3 (Fig. 7A) . As expected, the response of channels to 2-APB was strongly enhanced by extracellular acid (Fig. 7B) . At extracellular pH 6.3, normalized amplitudes of the 0.1 mM, 0.5 mM, and 1 mM 2-APB-evoked currents were 8-10-fold larger than the control responses. At pH 7.3 the currents activated by 10 M, 100 M, 500 M, and 1000 M 2-APB were 0.7 ± 0.2%, 0.9 ± 0.4%, 1.7 ± 0.5%, and 4.8 ± 1.5%, respectively (n = 4). At pH 6.3, they were increased to 1.8 ± 0.8%, 7.0 ± 3.0%, 35.3 ± 12.1% (p < 0.05), and 52.2 ± 12.5% (p < 0.01), respectively (n = 6; Fig. 8C) . The data clearly demonstrate that 2-APB stimulates the activation of rTRPV1 channels by heat and protons, i.e., they reciprocally sensitized each other.
Effect of 2-APB analogue DPBA
To define the pharmacological requirements for the 2-APB activation, the effect of structural analogue DPBA was examined on rTRPV1 with inside-out patches. As shown in Fig. 9A , I cap was enhanced by the cytoplasmic addition of 1 mM DPBA. Inclusion of 1 mM DPBA in the pipette solution increased I cap and the currents were further activated by 1 mM DPBA applied from the cytoplasmic side (Fig. 9B,Cw) . I cap at 10 M capsaicin (13.8 ± 4.6%) was significantly potentiated by extracellular DPBA (51.6 ± 8.1%, n = 7, p < 0.05). Similar to the effect of acid on the 2-APB current (Fig. 8) , intrapipette acid enhanced the DPBA-induced currents (recordings not shown).
The summarized data are shown in Fig. 9D . At pH 6.3, 1 mM DPBA-induced currents were significantly higher than control at pH 7.3 (1.16 ± 0.18%, n = 5 vs. 35.1 ± 14.0%, n = 4; p < 0.05; Fig. 9D ). Therefore, these data suggest that DPBA is an rTRPV1 agonist and shows similar response to that of 2-APB. 
Discussion
A synthetic organic compound, 2-APB has been commonly used as a general inhibitor of SOCE and TRP channels. Recently, it was shown that 2-APB is not only an inhibitor of many native and expressed TRPC and TRPM channels but also an activator of TRPV1, TRPV2, and TRPV3 channels. 16, 17 It has been postulated that TRP channels have a common 2-APB binding domain but the channel activity is differently affected by 2-APB. Among TRP channels, 2-APB at 10-100 M inhibits TRPC1, TRPC3, TRPC5, TRPC6, TRPM3, TRPM7, TRPM8, and TRPP2. 12, 16, 22, 23 At high concentrations (> 100 M), 2-APB selectively activates TRPV1, V2, and V3 channels. 16, 19 However, the stimulatory effect of 2-APB on these thermo-TRPV channels is not generally accepted, because it is suggested that the compound has no effect on TRPV2 and hardly activates TRPV1 expressed in HEK cells. 19 This discrepancy has been explained by the different concentrations of 2-APB used or by the different expression level of the channels. 16, 19 The present study attempted to demonstrate the effects of 2-APB on rTRPV1 channels expressed in HEK cells. Instead of whole-cell patch clamp recording, by which the 2-APB activation of TRPV1 was first reported, our results were obtained from excised patches, which excludes an intervention by cytosolic components. TRPV1 modulating molecules that might affect the response to 2-APB included protein kinase C, 20 protein kinase A, [24] [25] [26] calmodulin kinase II, 21 and regulators of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) metabolism. 27, 28 TRPV1 channels are easily rundown or desensitize in response to stimuli, and the contribution of protein kinase C and calmodulin kinase II on the desensitization has been reported. 20 PIP 2 is a substrate of phospholipase C and is known to inhibit TRPV1 through a specific domain of the channel. Furthermore, it is known that 2-APB activates phospholipase C in B lymphocytes and releases the stored Ca 2+ from endoplasmic reticulum. 15 The plasma membrane side of action for 2-APB has been suggested to be extracellular, because the intracellular application of 2-APB failed to activate TRPV1 and TRPV3 current in Xenopus oocytes and conventional whole-cell recorded HEK293 cells, respectively. 16, 29 To determine the 2-APB-binding sites, we applied 2-APB from either side of the membrane in the inside-out or outside-out patch configuration (Fig. 2) . We clearly demonstrated that 2-APB activates rTRPV1 channels not only from inside but also from the outside of the membrane. In the inside-out and outside-out modes, the perfusion of 2-APB-contained bath solution activated the channels in a dose-dependent manner, i.e., it stimulates the channels from the inside as well as the outside of the membrane. In whole-cell configuration, 2-APB also activated TRPV1 channels (Fig. 6) . Therefore, it clearly shows that 2-APB-binding sites are located on both sides of the membrane. To further confirm this, we included 2-APB inside of the recording pipettes of the inside-out or outside-out mode, thereby stimulating the channels from outside or inside of the membrane, respectively. To our surprise, however, it needed a higher concentration of intrapipette 2-APB (> 5 mM) to activate the channels sufficiently (Fig. 2) . This was an unexpected result, because < 500 M of 2-APB applied from the bath solution of the inside-out or outside-out patches readily activated a discernible current, regardless of the expression level of the channels. In the present study, we could not thoroughly explain the reason for this phenomenon. Chelation or adsorption of 2-APB by the glass pipette may be suggested but needs to be proved. When 2-APB was included in the patch pipette solution for the excised patches, accumulation of the membrane permeable 2-APB at the extrapipette side (bath solution) is hard to achieve as the drug will be rapidly diluted by the bath solution and will be washed away by perfusion. Therefore, activation of TRPV1 current by the intrapipette 2-APB in the excised patches (inside-out or outside-out modes) further supports that 2-APB can activate TRPV1 from both sides of the plasma membrane. Conversely, the membrane permeable 2-APB can accumulate at the pipette side even though it is applied to the extrapipette side of the excised patch membrane. 30 Activation of TRPV1, TRPV2, and TRPV3 channels by 2-APB has been reported by whole-cell recordings and [Ca 2+ ] i measurement. 16 Because 2-APB commonly activated TRPV1, TRPV2, and TRPV3, it is suggested that these channels share structural similarity and are gated by similar mechanisms. Interestingly, the sensitivity of channels to 2-APB, revealed by the order of half maximal effective concentration values, follows the order of temperature threshold of each channel: TRPV3 (> 32 • C), TRPV1 (> 43 • C), and TRPV2 (> 52 • C). To find the 2-APB-binding site, Hu et al 16 applied 1 mM 2-APB to the inside of the whole-cell recording pipette and waited more than 6 minutes after breaking the membrane of TRPV3-expressing HEK cells. However, they failed to record the TRPV3 current in this condition. Furthermore, they failed to activate TRPV1 expressed in Xenopus oocytes by the intracellular injection of 40 mM 2-APB. Based on these results, they suggested that 2-APB-binding sites are located at the extracellular side of the membrane. This is, however, clearly contradictory to our present data. We recorded TRPV1 current mainly by insideout patches, and the cytoplasmic perfusion of 2-APB activated the channels with no exception. In the outside-out patches, cytoplasmic application of 2-APB through the patch pipette activated the current, although it requires a relatively higher concentration. More interestingly, even in the presence of a higher concentration of 2-APB in the recording pipette (i.e., 5 mM 2-APB in the inside-out or outside-out patch pipettes), a low concentration of 2-APB applied from the opposite side of the membrane further activated the current (Fig. 2Aii, Bii) . There are two possible explanations for the responses. First, intracellular and extracellular 2-APB molecules cooperate or potentiate each other when they simultaneously occupy their binding sites, thus they produce a supra-additive response. As 2-APB does on capsaicin, heat, and protons to potentiate TRPV1, each 2-APB molecule from the opposite side of the membrane can potentiate each other to open the channels. Second, a simple additive effect of TRPV1 opening by 2-APB can be postulated. When 2-APB binds to the channel simultaneously from the inside and outside of the membrane, they independently activate the channels without any interruption to the opposite. We think that the former seems plausible, because the current activated by the first arrived 2-APB is always smaller than the current activated by the latter (Fig. 2) .
In contrast to our results that show two 2-APB-binding sites on rTRPV1, it has been suggested that the blocking site of TRPC3, C5, V1, and V3 channels by 2-APB is located only at the extracellular face. 12, 16, 23 In expressed human TRPC5 channels, it was suggested that one 2-APB molecule binds per channel with mild voltage-dependence and the extracellular blocking site is exclusive for 2-APB without sharing with other Ca 2+ channel blockers. 12 We could not completely explain the reason for this discrepancy, and it remains to be elucidated.
It has been shown that 2-APB stimulates the response to capsaicin, heat, acid, and sensitizes native TRPV1-expressing nociceptive neurons to heat in a mouse model. 16, 18 Our present study strongly supports this suggestion. We clearly demonstrate evidence supporting the stimulatory roles of 2-APB on the heterologously expressed TRPV1 by using the cell-free, excised patch clamp: (1) 2-APB directly activates rTRPV1 (Fig. 2, 10) ; (2) 2-APB and capsaicin reciprocally potentiate the stimulatory effect on rTRPV1 (Fig. 3-6) ; (3) 2-APB potentiates the response to heat and protons (Fig. 7, 8) ; and (4) DPBA potentiates the response to capsaicin and protons (Fig. 9) .
It still remains a mystery how 2-APB activates and sensitizes the capsaicin-activated TRPV1 channel. In Xenopus oocytes expressing TRPV1, 2-APB left-shifted the doseresponse curves for capsaicin and the pH dependence by several fold. Conversely, capsaicin left-shifted the doseresponse curve to 2-APB several-folds. 16 We showed that 2-APB applied from the cytoplasmic side (Fig. 3) or extracellular side (Fig. 5 ) sensitized capsaicin-evoked rTRPV1 current and shifted the dose-response curve to the left, which is in accordance with previous suggestions. 16 TRPV1 can be activated by a number of lipophilic molecules. 31 Increasing the content of the plasma membrane cholesterol lowers the temperature sensitivity and shifts the threshold of TRPV1 to higher temperature range, and the membrane PIP 2 hold TRPV1 in an inhibitory state. 28, 30 2-APB is a lipophilic molecule and can accumulate in the plasma membrane bilayer at higher concentrations. Therefore, 2-APB could disrupt the interaction between TRPV1 and the inhibitory membrane lipids (PIP 2 and cholesterol) and sensitize the channel to various agonists. 30 Because the effects of 2-APB on TRPV1 channels require a higher concentration and are relatively nonspecific, at present, it is unlikely to be used for therapeutic and clinical uses. Chemical modification of the structure of 2-APB can generate various analogs with greater differences in the affinity and selectivity to TRPV1 channel and/or TRPV1-interacting molecules to enhance or reduce the channel activity. If the chemically modified 2-APB analogs have highly specific TRPV1 inhibitory activities at lower concentrations, they can be used as therapeutic tools to reduce TRPV1-mediated inflammatory pain. In addition, 2-APB analogs can be used for the development of a specific antagonist for SOCE channels, which are pivotal for many immunological and cardiovascular diseases. Recent progress on the synthesis of 2-APB analogs with higher specificity for SOCE channel should certainly accelerate the discovery of therapeutic drugs for many TRP channel-related diseases. 32 In conclusion, our data suggest that 2-APB directly opens rTRPV1 channels and strongly potentiates the effects of wellknown TRPV1 agonists. Binding sites of 2-APB on TRPV1 channels are judged to be located on both sides of the membrane. Because DPBA shows the same effects, it is suggested that 2-APB and its analogs could be attractive candidates for the development of a selective TRPV1 agonist and/or antagonist.
